Trial Profile

A pilot study to evaluate the safety, tolerability and efficacy of obeticholic acid (INT-747) for the treatment of portal hypertension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jan 2014 New trial record
09 Jan 2014 Results of this trial have been submitted for presentation at the International Liver Congress of the European Association for the Study of the Liver (EASL) in April 2014, according to an Intercept Pharmaceuticals media release.
09 Jan 2014 Results from this trial support the initiation of a double-blind phase IIB trial of obeticholic acid in the treatment of portal hypertension, according to an Intercept Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com